<DOC>
	<DOCNO>NCT00156104</DOCNO>
	<brief_summary>Schizophrenia brain disease . The primary feature schizophrenia characterize Positive symptom ( symptom , inability think clearly , distinguish reality fantasy i.e. , hear voice ) Negative symptom ( reduction absence normal behavior emotion , i.e. , unable manage emotion , make decision relate others ) . Other symptom include reduced ability recall learn new information , difficulty problem solve , maintain productive employment . The symptom schizophrenia may due imbalance chemical brain , primarily dopamine serotonin , enable brain cell communicate . Asenapine investigational drug may help correct inbalance dopamine serotonin . This 6-week trial test efficacy safety asenapine , compare placebo , use active comparator agent ( haloperidol ) treatment patient acute exacerbation schizophrenia . Patients complete 6-week trial option continue additional one year extension trial .</brief_summary>
	<brief_title>Efficacy Safety Asenapine With Placebo Haloperidol ( 41023 ) ( P05926 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>Currently suffer acute exacerbation schizophrenia . Caregiver require . Have uncontrolled , unstable medical condition . Have pyschiatric disorder schizophrenia primary diagnosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>